Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3177-3184

  Maciejczyk, Adam ^a   Szelachowska, Jolanta ^a,b   Ekiert, Marcin ^a,b   Matkowski, Rafał ^a,b   Hałoń, Agnieszka ^b   Lage, Hermann ^c   Surowiak, Paweł ^b  

^a Silesian Oncological Centre   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; Early stage cancer; Prognostic biomarker; YB1

Indexed keywords

MONOCLONAL ANTIBODY; Y BOX BINDING PROTEIN 1;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CYTOPLASM; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EARLY CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; Y-BOX-BINDING PROTEIN 1;

EID: 84865683551     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, Forman C, Mathers C and Parkin DM: Globocan 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancerbase No. 10. Lyon, France: International Agency for Research on Cancer, 2010.
2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ, Panel members: Threshold for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20: 1319-1329, 2009.
3. Schittek B, Psenner K Sauer B, Meier F, Iftner T and Garbe C: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120: 2110-2118, 2007.
4. Mantwill K, Köhler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A and Surowiak P: Inhibition of the multidrug-resistant phenotype by targeting YB1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 15: 7195-202, 2006.
5. Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, Ono M, Nishio K, Kuwano M and Tsuneyoshi M: Prognostic implications of the nuclear localization of Y-boxbinding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated AKT, LRP/MVP and P-glycoprotein expression. Cancer Sci 98: 1020-1026, 2007.
6. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B and Royer HD: Nuclear localization and increased levels of transcription factor YB1 in primary human breast cancer are associated with intrinsic MDR1 gene expression. Nature Med 3: 447-450, 1997.
7. Saji H, Toi M, Saji S, Koike M, Kohno K and Kuwano M: Nuclear expression of YB1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 190: 191-197, 2003.
8. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D and Dunn SE: Redefining prognostic factors for breast cancer: YB1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: 2-9, 2008.
9. Gessner C, Woischwill C, Schumacher A, Liebers U, Kuhn H, Stiehl P, Jürchott K, Royer HD, Witt C and Wolff G: Nuclear YB1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J 23: 14-19, 2004.
10. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, Garami M, Bognár L, Hanzély Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietsch T, Albrecht S and Jabado N: Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB1 expression in tumors. J Clin Oncol 25: 1196-1208, 2007.
11. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M and Tsuneyoshi M: Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression and with poor prognosis in synovial sarcoma. J Pathol 199: 251-258, 2003.
12. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M and Iwamoto Y: Nuclear expression of YB1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4: 2273-2277, 1998.
13. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME and Nelson CC: YB1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59: 337-349, 2004.
14. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M and Royer HD: Y-box factor YB1 predict drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97: 278-282, 2002.
15. Szczuraszek K, Halon A, Materna V, Mazur G, Wrobel T, Kuliczkowski K, Donizy P, Holm PS, Lage H and Surowiak P. Elevated YB1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res 31: 2963-2970, 2011.
16. Sobin LH and Wittekind C. TNM Classification of malignant tumors, Wiley-Liss, New York, USA, 5th edition, 1997.
17. Madden JL: Modified radical mastectomy. Surg Gynecol Obstet 121: 1221, 1965.
18. Auchincloss H: Modified mastectomy. Surg Gynecol Obstet 119: 506, 1970.
19. Bloom H and Richardson W: Histological grading and prognosis in breast cancer: study of 1409 cases of wich 359 have been followed for 15 years. Br J Cancer 11(3): 359-77, 1957.
20. Genesti C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A and Sastre-Garaux X: Comparison of the prognostic value of Scarff-Bloome-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems. Anticancer Res 18: 571-576, 1998.
21. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
22. Stanisz A: Accessible course of statistics using STATISTICA PL on examples from medicine (in Polish). Kraków, Poland, Statsoft, 2007.
23. Kohno K, Izumi H, Uchiumi T, Ashizuka M and Kuwano M: The pleiotropic functions of the Y-box-binding protein, YB1. BioEssays 25: 691-698, 2003.
24. Wolffe AP: Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bio Essays 16: 245-251, 1994.
25. Tafuri SR and Wolffe AP: DNA binding, multimerization, and transcription stimulation by the Xenopus Y box proteins in vitro. New Biologist 4: 349-359, 1992.
26. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K and Kuwano M: Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS, Lett 417: 390-394, 1997.
27. Swamynathan SK, Nambiar A and Guntaka RV: Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes. FASEB 12: 515-522, 1998.
28. Holm PS, Bergmann S, Jurchott K, Lage H, Brand K, Ladhoff A, Mantwill K, Curiel DT, Dobbelstein M, Dietel M, Gansbacher B and Royer HD: YB1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem 277: 10427-10434, 2002.
29. Mantwill K, Köhler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R, Gansbacher B and Holm PS: Inhibition of the multidrug-resistant phenotype by targeting YB1 with a conditionally oncolytic adenovirus: Implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 66: 7195-7202, 2006.
30. Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M: Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 68: 1504-1512, 2008.
31. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB and Dunn SE: Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66: 4872-4879, 2006.
32. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U and Harbeck N: Y-Box-binding protein YB1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 27: 6144-6151, 2009.